NASDAQ / LIVE COMPANY INTELLIGENCE

Jyong Biotech Ltd.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERMENS
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / MENS COVERAGE

What’s moving Jyong Biotech Ltd. now

Current reporting with the operating signal separated from the noise.

01
Jyong Biotech Ltd.: Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships

Jyong Biotech Ltd.: Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships

The story matters when it changes Jyong Biotech Ltd.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025

Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025

The story matters when it changes Jyong Biotech Ltd.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Jyong Biotech Ltd.: Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS-2

Jyong Biotech Ltd.: Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS-2

The story matters when it changes Jyong Biotech Ltd.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS ...

Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS ...

The story matters when it changes Jyong Biotech Ltd.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention

Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention

The story matters when it changes Jyong Biotech Ltd.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest MENS filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

20-FOfficial SEC filingFiled 2026-05-15 · Period 2025-12-31SEC ↗6-KOfficial SEC filingFiled 2026-02-06 · Period 2026-02-06SEC ↗NT 20-FOfficial SEC filingFiled 2026-04-29 · Period 2025-12-31SEC ↗SCHEDULE 13DOfficial SEC filingFiled 2026-04-24SEC ↗3Official SEC filingFiled 2026-04-14 · Period 2026-04-13SEC ↗3Official SEC filingFiled 2026-04-08 · Period 2026-04-08SEC ↗3Official SEC filingFiled 2026-04-01 · Period 2026-04-01SEC ↗3Official SEC filingFiled 2026-04-01 · Period 2026-04-01SEC ↗
EARNINGS / QUARTERLY TRACKER

Jyong Biotech Ltd., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.